Table 1 Clinical features, monocyte matrix metalloproteinase (MMP) and tissue inhibitor of matrix metalloproteinases (TIMP) expression in controls and in Type 2 diabetes patients

n

18

22

Age (yrs)

51.7 (8)

56.0 (8) *

Male : Female

14:4

16:6

Diabetes duration (yrs)

N/A

6.5 (5.9)

BMI (kg/m2)

26.6 (6.0)

27.4 (7.2)

HbA1c (%)

5.1 (0.4)

7.0 (1.4) **

Fasting plasma glucose (mmol/l)

4.7 (0.7)

8.6 (2.9) **

Treatment

Aspirin

0

0

Statin

0

0

Diet alone

-

6

Sulphonylurea alone

-

8

Metformin alone

-

3

Combination

-

5

MMP-1 (ng/ml)

5.5 (5)

6.4 (5.9)

MMP-3 (ng/ml)

0.0 (1.2)

0.0 (0.8)

MMP-9 (ng/ml)

42.1 (82)

48.2 (51)

TIMP-1 (ng/ml)

192.9 (108)

163.0 (111)